|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that DLBCLs are dependent on mitochondrial lysine deacetylase SIRT3 for proliferation, survival, self-renewal, and tumor growth in vivo regardless of disease subtype and genetics.
|
31185214 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ZEB1 transcriptionally silenced expression of SIRT3, a mitochondrial-localized tumor suppressor, through interaction with MBD1.
|
30487699 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of SIRT3 suppressed mTORC1 and growth in vivo in a xenograft tumor model of breast cancer.
|
29466723 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher Sirt3 is significantly correlated to advanced tumor grade (<i>P</i>=0.004), showing its potential role in cancer progression.
|
30464504 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sirtuin 3 (Sirt3) has a promising role in cancer tumourigenesis and treatment, but there have been controversies about its role as oncogene or tumour suppressor in different types of cancer.
|
29683756 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our data revealed that Sirt3 is an anti-inflammatory and tumor-suppressing gene that interacts with the gut microbiota during colon tumorigenesis.
|
29650970 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia.
|
29930768 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mean of the largest diameter was smaller in adenomas with SIRT1 overexpression than with normal expression (P < 0.01) and SIRT3 underexpression was associated with larger tumors (P < 0.01).
|
29564694 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SIRT3 expression was obviously associated with tumor size (odds ratio [OR]=1.41, 95% CI=1.02-1.94, <i>P</i>=0.04), tumor differentiation (OR=1.52, 95% CI=1.08-2.16, <i>P</i>=0.02) and clinical stage (OR=2.07, 95% CI=1.23-3.46, <i>P</i>=0.01) in HCC.
|
29713184 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent deacetylases and mitochondrial SIRT3 is known to be a tumor suppressor via its ability to suppress ROS and hypoxia inducible factor 1α (HIF-1α).
|
29108235 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT3 may drive both oncogenic and tumor-suppressive effects.
|
28634345 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results elucidated the function of SIRT3 in hepatocellular carcinoma development and suggested that SIRT3 might function as tumor suppressor in hepatocellular carcinoma by targeting PI3K/Akt pathway.
|
28347248 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show that HKL-mediated activation of SIRT3 also protects the heart from doxorubicin-induced cardiac damage without compromising the tumor killing potential of doxorubicin.
|
28423723 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chi-square tests indicated that the expression of SIRT3 correlated with T status (p<0.001) and tumor stage (p=0.013).
|
28867266 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrated that targeting the maintenance of healthy mitochondria with increased mitochondrial NAD<sup>+</sup> levels and SIRT3 activity could be a promising strategy for abolishing the development of TICs as a new therapeutic approach to treating aging-associated tumors.
|
28604662 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth.
|
28536275 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT3 is a tumor suppressor, and deacetylation of these enzymes contributes to its biological function.
|
28512002 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human sirtuin-3, a protein involved in the mediation of tumors, has been shown to be present in malignancies.
|
29243781 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry results showed that SIRT3 in the tumor tissue sample was positive in 19 patients out of 32 HCC patients; however, there was no strong positive case, the positive rate of SIRT3 expression was 59.38% (19/32).
|
28338198 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis demonstrated that lymph node metastasis, the tumor size, and SIRT3 expression were independent prognostic factors for NSCLC patients.
|
28947845 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIRT3: Oncogene and Tumor Suppressor in Cancer.
|
28704962 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of mitochondrial tumor suppressor genes (SIRT3, SIRT4 and MTUS1), mitochondrial DNA repair gene (OGG1-2a) and a proliferation marker (Ki-67) was studied in a study cohort of 120 HNSCC patients and controls with reverse transcriptase polymerase chain reaction (RT-PCR) and real-time PCR (qPCR) in order to determine the potential prognostic significance of these genes.
|
26785117 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study suggests that SIRT3 acts as a tumor suppressor in B cell malignancies, and activating the SIRT3 pathway might represent a novel therapeutic approach for treating B cell malignancies.
|
26631723 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sirtuin, an aging-related gene involved in mitochondrial metabolism, is associated with life span, and more importantly, murine models lacking Sirt3 spontaneously develop tumors that resemble human luminal B breast cancer.
|
26935174 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sirtuin-3 (SIRT3), a member of the NAD(+)-dependent Class III histone deacetylases, may function as different role depending on the cell-type and tumor-type.
|
27216459 |
2016 |